Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Feasibility and Prospective Randomized Study of Transarterial Chemoembolization using Irinotecan Bead in Combination with Second Line Chemotherapy in the Treatment of Patients with Unresectable Metastatic Colorectal Cancer (PARAGON)

Next Previous
Trial Profile

Feasibility and Prospective Randomized Study of Transarterial Chemoembolization using Irinotecan Bead in Combination with Second Line Chemotherapy in the Treatment of Patients with Unresectable Metastatic Colorectal Cancer (PARAGON)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Irinotecan
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms PARAGON-I

    • Most Recent Events

    • 26 Aug 2010 The trial has received FDA approval for continuing into a randomised phase IIb trial, with results expected in 2012, as reported in a Biocompatibles International media release.
    • 03 Jul 2010 Promising results have been presented at the World Congress for Gastro-Intestinal Cancer, as reported in a Biocampatibles International media release.
    • 16 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top